CHICAGO, May 3 (Reuters) – An experimental Alzheimer’s drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what … [+4726 chars]Read More
Lilly drug slows Alzheimers by 35 bolstering treatment approach Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/QHGRP7VJ2NN65A24ECZMXBQTOY.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/GITAKD37GBNXDI6725B3GOPGW4.jpg)